An Evolution of Executive Search: Navigating a Changing Landscape
AI is commoditizing search, squeezing retained fees, and pushing hiring toward contingent, hybrid, and DIY models. Only firms that add value beyond a shortlist will... Read more.
Biotech: Where Failure is Likely, Money Is Fleeting, and Layoffs are Inevitable
Clinical drug development is costly and has a failure rate over 90%, necessitating significant external funding for small companies. As mergers and acquisitions... Read more.